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Background: Radical cystectomy with pelvic lymph node dissection represents the standard treatment for
muscle-invasive, and high-risk non-muscle-invasive bladder cancers. Aim of this study was to report our case series
of 30 patients undergoing totally laparoscopic radical cystectomy (LRC) with reconstruction of an intracorporeal
orthotopic ileal neobladder. Intra- and perioperative results and the functional and oncological outcomes 9 months
after operation are reported.
Methods: Between October 2010 and December 2012, 30 male patients underwent LRC with a pure laparoscopic
orthotopic ileal “U”- shaped neobladder diversion. The men had a median age of 67 years, a median body mass index
of 22.3, and a mean ASA score of 2.2; they represented various clinical stages of disease.
Results: None of the patients required conversion to open surgery, and no perioperative mortalities were reported.
The median operating time was 365 min, and the median blood loss was 290 mL, with a transfusion rate of 26.6%.
All surgical margins were negative; 8 patients with non–organ-confined disease or positive lymph nodes received
adjuvant chemotherapy. Early complications (within 30 days) occurred in 7 patients, and late complications occurred in
6 patients. The mean hospital stay was 9 days. At 9 months after surgery, the daytime continence rate was 83.3% and
the nighttime continence rate was 73.3%.
Conclusions: Pure LRC with intracorporeal orthotopic ileal neobladder reconstruction may represent a viable
alternative to open radical cystectomy, with a significant reduction in patient morbidity. Future, large, randomized
controlled trials with extensive follow-up are needed to confirm our encouraging results.
Keywords: Laparoscopic radical cystectomy, Orthotopic neobladder, Urinary diversion, Ileal neobladder, Bladder cancerBackground
Radical cystectomy (RC) with pelvic lymph node dissec-
tion (PLND) and urinary diversion is still considered the
gold standard treatment for muscle invasive bladder can-
cer [1]. To reduce morbidity and decrease the duration of
hospitalisation, minimally invasive surgical approaches
have been described since 1992, when laparoscopic radical
cystectomy (LRC) was first reported [2,3]. Technical diffi-
culties and high costs have hampered the widespread* Correspondence: antopast@hotmail.com
1Department of Medico-Surgical Sciences and Biotechnologies, Faculty of
Pharmacy and Medicine, Urology Unit ICOT, Sapienza University of Rome, Via
Franco Faggiana 1668, Latina 04100, Italy
5Uroresearch Association, non-profit research, Latina, Italy
Full list of author information is available at the end of the article
© 2014 Pastore et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.adoption of this technique [4], but its broader use is being
facilitated by the development of new dissection and
haemostatic devices that allow precise topographic defin-
ition of the surgical field and which simplify some surgical
steps. As a result, better oncologic and functional out-
comes have been reported [5].
The purely intracorporeal reconstruction of an orthoto-
pic neobladder was not performed until 2000 [6]. Since
then, expertise with laparoscopic surgery has increased,
with a greater interest in this procedure being developed
and the consequent report of a variety of reconstructive
options. LRC and robot-assisted RC (RARC) with different
urinary diversion methods have been demonstrated to be
feasible, safe, and capable of providing many operativeLtd. This is an Open Access article distributed under the terms of the Creative
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reports describing the perioperative, oncologic, and func-
tional outcomes in case series involving totally intracor-
poreal neobladder reconstruction. Herein, we report the
results of LRC that involved a complete, intracorporeal,
orthotopic, “U”-shaped, ileal neobladder in 30 patients,
with a median follow-up period of 16.5 months (max-
imum, 32 months).
Methods
Between December 2010 and December 2012, 30 con-
secutive patients underwent LRC with intracorporeal
orthotopic neobladder reconstruction in our department.
The study was performed according to the Ethical Princi-
ples for Medical Research Involving Human Subjects
(World Medical Association, The Declaration of Helsinki
Principles, 2000). A local ethical committee approval was
obtained (ASL Lt/no.12834652/2010). Written informed
consent was obtained from all patients. The inclusion
criteria for this procedure included (1) muscle-invasive,
urothelial bladder cancer T2–4a, N0–Nx, M0; (2) high-
risk or recurrent non–muscle-invasive tumours or multi-
focal T1G3; and (3) T1G3 with concomitant carcinoma
in situ (CIS). Patients were not eligible for this procedure
according to the following criteria: (1) patient refusal of
LRC with orthotopic diversion; (2) the presence of an
LRC contraindication, including distant metastases, an
American Society of Anaesthesiologists (ASA) score >3,
severe heart and/or respiratory failure; and (3) the pres-
ence of contraindications to neobladder diversion, includ-
ing the presence of an urethral tumour, urethral stricture,
extensive abdominal surgery, or severely insufficient renal
function. Relative contraindications were an age >75 years
and a body mass index (BMI) >30.
Surgical techniques
Cystoprostectomy
Each patient was placed in a supine, steep Trendelenburg
position (20–25°), and pneumoperitoneum (12 mmHg)
was established. A five-port, fan-shaped, transperitoneal
approach was used, according to the Hasson technique
[9]. Bilateral pelvic lymphadenectomy was performed as
the first step. The boundaries of standard PLND were
the bifurcation of the common iliac artery, proximally;
the genitofemoral nerve, laterally; the circumflex iliac
vein and lymph node of Cloquet, distally; and the hypo-
gastric vessels, posteriorly, including the obturator fossa.
Extended PLND (in order to reach the aortic bifurcation)
was performed in all cT3 cases and when computed tom-
ography revealed a pelvic lymphadenopathy.
After PLND, a 7- to 8-cm transverse peritoneal incision
of the pouch of Douglas was made with a 5-mm Ligasure
(Covidien, Boulder, CO, USA). The umbilical ligaments
and the urachus were divided, proximally, allowing entryinto the space of Retzius to mobilise the bladder. The
ampullae of the vas deferens were transected bilaterally,
and the seminal vesicles were dissected and maintained,
en bloc, with the bladder using a 5-mm Hem-o-lok
(Teleflex Medical, Research Triangle Park, NC, USA)
(Figure 1A). The Denonvilliers’ fascia was then incised,
and a Denonvilliers’ space between the rectum and the
prostate was developed. The endopelvic fascia was incised
bilaterally, and the puboprostatic ligaments and the dorsal
vein complex were dissected with the Ligasure device. The
ureters were isolated, bilaterally, ligated, and transected
with cold scissors, just outside the bladder; the distal mar-
gins of the ureters were also sent for frozen section biopsy.
The lateral pedicles of the bladder and the prostate were
bilaterally isolated and divided with Hem-o-lok. In cases
where we attempted a nerve-sparing procedure, an intra-
fascial dissection was performed at the dorso-lateral part
of the prostate. Hem-o-lok clips were used to avoid ther-
mal injury to the neurovascular bundles during cautery.
The apex of the prostate, the urethra and the recto-
urethral muscles were divided using scissors.
Neobladder reconfiguration
A 40-cm segment of ileum, 20 cm from the ileocecal
junction, was isolated, and ileo-ileal continuity was re-
stored using Endo-GIA staplers (U.S. Surgical, Norwalk,
CT, USA). The isolated ileal segment was detubularised
and a globular U-shaped ileal neobladder was con-
structed (Figure 1B) and anastomosed to the urethra
with two 15-cm, 3–0 barbed sutures (Filbloc 90 day
absorbable suture, Assut Europe, Rome, Italy), using the
Van Velthoven technique (Figure 1C) [10]. Each ureter
was spatulated for a length of 2 cm and separately anas-
tomosed to the terminal ends of the U-shaped ileal
segment, using the Le Duc technique with continuous,
3–0 barbed sutures (Figure 1D) [11]. After suturing the
posterior wall, two single-J, 7-Ch, 40-cm ureteral stents
were inserted, using the Seldinger technique, through the
abdominal wall, at the midline, just above the symphysis
[12]. The stents were placed in the ureters through a 2-
mm MiniPort trocar (Covidien), positioned just above
the symphysis. The entire procedure was performed intra-
corporeally. The neobladder was irrigated to ensure a
watertight closure; any leaks were secured with inter-
rupted 2–0 Vicryl sutures. A suction drain was placed in
the pelvis through a lateral port site.
The postoperative care included removal of the naso-
gastric tube on postoperative day 1; pouch irrigation
every 8 hours starting on postoperative day 1; and
removal of the abdominal drain when the output
was <200 mL/day. The ureteral stents were removed
7 days postoperatively and a cystography control was
obtained at 3 weeks and, if no leaks were observed,
the catheter was removed.
Table 1 Patient demographics and clinical data
Characteristic Value
Age, median (range), years 67 (62–79)
BMI, median (range), kg/m2 22.3 (16.0–26.1)
ASA score, No. (%) 1) 9 (30)
2) 15 (50)
3) 6 (20)
Clinical stage, No. (%) cT1, 12 (40)
cT2, 16 (53.3)
cT3, 2 (6.6)
Figure 1 Key surgical steps of cystectomy and ileal neobladder reconfiguration. A. Seminal vesicles and vas deferens were dissected
and maintained en bloc with the bladder, using a 5 mm Hem-o-lok. B. “U-Shaped” neobladder configuration with stapler device. C. The
neoblader-urethral anastomosis is completed with two Filbloc running barbed 3–0 sutures. D. Neobladder-ureteral anastomosis with Filbloc
running barbed 3–0 suture.
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Demographic and operative data
The demographic data are summarized in Table 1. The
30 male patients had a median age of 67 years, a median
BMI of 22.3, and a mean ASA score of 2.2. None of the
patients had prior radiation treatment, 3 had received
neoadjuvant chemotherapy, and 9 had failed intravesical
instillation of bacillus Calmette-Guérin.
The operative data are presented in Table 2. None of the
cases required conversion to open surgery, and no peri-
operative mortalities were reported. The median operating
time was 365 min, with a median blood loss of 290 mL
and a transfusion rate of 26.6%. The mean number of
lymph nodes removed was 16 (range, 5–28). Overall, the
median hospitalization duration and times to regular diet
and ambulation were 9 (range, 7–37) days, 6 days, and
2 days, and, respectively.Concomitant CIS, No. (%) 7 (23.3)
Primary tumour, No. (%) 16 (53.3)
Recurrence after operations with
intravesical BCG therapy, No. (%)
9 (30)
Neoadjuvant chemotherapy No. (%) 3 (10)
Smoking history, No. (%) 21 (70)
Previous abdominal surgery, No. (%) 8 (26.6)
Other malignancies, No. (%) 3 (10)
BMI = body mass index; ASA = American Society of Anaesthesiologists;
BCG = Bacillus Calmette-Guérin; CIS = carcinoma in situ.Pathologic data
The pathologic data are summarized in Table 3. All
tumours were transitional cell carcinomas, but 30%
(9/30) of the patients had concomitant carcinoma in
situ; incidental prostate cancer was detected in 26.6%
(8/30) of the patients. All surgical margins were negative,
but 8 patients, with non–organ-confined disease or posi-
tive lymph nodes, received adjuvant chemotherapy.
Table 2 Operative data
Characteristic Median value (range)
Operative time, min 365 (270–605)
Estimated blood loss, mL 290 (70–800)
Pelvic lymph nodes removed 16 (range, 5–28)
Transfusion rate, % 26.6
Time to liquid consumption, days 3 (2–7)
Time to regular diet, days 6 (4–11)
Time to ambulation, days 2 (2–4)
Length of hospital stay, days 9 (7–37)
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The complications that were encountered are presented
in Table 4, along with their management. Complications
were classified as early, if they occurred within the first
30 postoperative days, or late (>30 days after surgery). The
complications were graded according to the modified
Clavien classification system [13]. Early complications
occurred in 8 patients (26.2%), including 7 presenting low-
grade complications (Clavien grades 1–2) and 1 patient
with high-grade complications (Clavien grades 3–5). Late
complications occurred in 9 patients (Clavien grade 1, 3
patients; Clavien grade 2: 2 patients; Clavien grade 3a: 3
patients; Clavien grade 3b, 1: patient). Kaplan MeierTable 3 Pathologic data



















Concomitant CIS 9 (30)
Incidental prostate cancer 8 (26.6%)
Positive surgical margins 0curves were used to evaluate the occurrence of low and
high grade complications. The overall and low/high grade
complications free survival up to 90 days of follow-up
were showed in Figure 2 (A, B, C). Low grade complica-
tion occurred more frequently during the first 20 days
postoperatively (Figure 2B), and significantly earlier when
compared to high grade complications (p = 0.001). All
high grade complications occurred after at least 32 days
(Figure 2C).
Functional outcomes
At the 9-month post-surgical follow-up visit, the daytime
continence rate was 83.3% (25/30 patients) and the night-
time continence rate was 73.3% (22/30 patients). The
mean maximal neobladder capacity was 295 mL, with a
mean post-void residual volume of 54 (range, 0–220) mL
and a peak flow rate of 13.6 (9.7–33) mL/s. Three patients
needed intermittent self-catheterization for chronic urin-
ary retention (>150 mL).
Follow-up data
The median follow-up duration was of 16.5 (range, 9–32)
months, with 11 patients (36.6%) completing 2 years of
follow-up. At the last outpatient visit (September 2013),
22 patients (73.3%) were alive without evidence of recur-
rence, 2 patients had both local recurrence and distant
metastases, 1 patient had local recurrence, and 1 patient
had distant metastasis. Five patients (16.6%) died from
various causes: 3 from metastases (multiple sites) and 2
from causes unrelated to the bladder cancer (1 from myo-
cardial infarction, 1 from a car accident).
Discussion
Laparoscopic surgery has improved considerably over
the last decade, with indications now including difficult
and prolonged procedures, such as radical cystectomies.
Since the first LRC was described in 2000, numerous
centres have published their experiences with this pro-
cedure [6,14]. However, very few centres have reported
data for more than 50 LRCs. Therefore, open RC still
represents the reference standard treatment for muscle
invasive bladder cancer whilst LRC is quickly emerging
as a viable and safe alternative in high volume centres.
Minimally invasive robotic and laparoscopic approaches
have shown technical promise and are being increasingly
adopted, as comparisons of perioperative and pathologic
features have demonstrated encouraging results [15,16].
However, concerns about the long-term oncologic effi-
cacy of RARC/LRC remain to be fully addressed with
large, prospective, long-term, follow-up studies.
In the current study, we presented data regarding our
experience with LRCs, involving pure intracorporeal
neobladder diversions, all performed by one skilled lap-
aroscopic surgeon assisted by the same surgical team.
Table 4 Complications, according to the modified Clavien classification system
Grade Complication No. of cases (%) Management
Early (within 30 day of LRC) 8 (26.6)
Low grade (1–2) 7 (23.3)
1 Wound infection 2 Antibiotics and bedside management
2 Delirium 2 Sedative
2 Deep venous thrombosis 1 Anticoagulation prolonged therapy
2 Bowel ileus 1 Conservative
2 Neobladder-urethral anastomosis leakage 1 Prolonged bladder catheterisation
High grade (3–5) 1 (3.3)
3a Uretero-pouch anastomosis stricture 1 Double-J indwelling stent
Late (>30 d after LRC) 9 (30)
Low grade (1–2) 5(16.6)
1 Chronic urinary retention 3 Intermittent self catheterisation
2 Deep venous thrombosis 1 Anticoagulation prolonged therapy
2 Pouchitis 1 Antibiotics
High grade (3–5) 4 (13.3)
3a Vesico-urethral anastomosis stricture 3 Endoscopic incision
3b Ileal-pouch fistula 1 Reoperation
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invasive bladder cancer can be successfully managed
by LRC. In fact, we achieved operating times, intra-
operative blood losses, and hospitalisation times com-
parable with those reported in the largest published
series; the overall complication rate was also similar to the
data reported in the literature. The type of complications
that were encountered confirmed the safety of the proced-
ure. Specifically, 70% (12/17 patients) required conserva-
tive treatment, without further surgical intervention, and
were classified as being “low-grade,” complications, based
on their Clavien classification (1 and 2); the remaining 5
patients required re-operations (4 needed minimally inva-
sive endoscopic procedures, and 1 required major open
surgery due to an ileal pouch fistula that developed 56 days
after LRC). The major complication rate reported in our
study remains less than that for open RC procedures and
was comparable to previously published experiences.
Haber et al. compared 25 consecutive LRCs with a con-
temporary cohort of 25 open RCs with urinary diversions
(14 ileal conduits, 11 orthotopic neobladders). The opera-
tive times, blood losses, transfusion rates, and incidence of
ileus were lower in the LRC group. Additionally, there
were no significant differences between the groups with
regard to oral intake, times to ambulation, postoperative
complications, or hospitalization stays [17]. The largest
LRC series, to date, reported by Huang et al., included 171
patients [18]. Their median operative time was 325 min,
with a median blood loss of 270 mL. They reported a total
complication rate of 39.2% (67/171), with 6.4% (11/171
patients) having Clavien I complications, 19.3% (33/171)having Clavien II complications, and 13.5% (23/171)
having Clavien III complications. Considering that the
other experiences reported in the literature describe
more complications in patients who had orthotopic
neobladder substitutions, as compared to ileal conduits,
this would explain why Huang et al. reported a higher
complication rate than that observed in other studies;
they only performed neobladder procedures.
There is significant variability in the results reported
regarding operative data, as well as complication rates.
These data reflect the available surgical expertise and
the volume of procedures conducted in the different
centres, and highlights the absence of consensus regarding
the operative procedures and urinary diversion techniques
used in laparoscopic surgery. In a retrospective study,
Aboumarzouk et al. compared 155 patients who under-
went LRC or open RC, with a mean follow-up period of
53 months. In this trial, the open RC group had shorter
operative times (p <0.0001), more blood loss, higher trans-
fusion requirements (p <0.00001), and longer hospitalisa-
tions than did the LRC group. No differences were found
regarding lymph node yields, positive margins, pathologic
results, or positive lymph nodes. The open RC group ex-
perienced fewer intraoperative complications (p =0.03).
Significant differences were not found between the two
groups regarding 5-year overall survival, cancer-specific
survival, and recurrence-free survival. The authors con-
cluded that LRC may be considered an alternative to open
RC with good operative results, in addition to comparable
oncologic outcomes [19]. Another 2 recent systematic
reviews evaluated 19 studies comparing open RC to LRC
Figure 2 90 day complications free survival in patients treated with laparoscopic radical cystectomy. A) Overall; B) Low grade
complications; C) High grade complications.
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superiority for one modality over the others [20,21]. The
authors also reported that despite the selected cohort of
patients included in the LRC and RARC groups, com-
pared to the non-selective ORC group, they were unable
to show a significant impact on oncological outcomes.
However, both reviews agreed that the LRC and RARC
results are encouraging and supported the diffusion of
these minimally invasive techniques.
New evidence seems to suggest that improved surgical
skills and experience helps with the replacement of open
RC with LRC. Robotic techniques are rapidly replacing
laparoscopy due to the shorter learning curve and similar,
if not better, operative and post-operative results. In a pro-
spective, comparative analysis between LRC and RARC
procedures involving ileal conduit urinary diversions,
Abraham et al. reported that both LRC and RARC cystec-
tomies can be safely performed without compromising
oncologic standards for surgical margins or the extent of
lymphadenectomy. The robotic approach appears to havea shorter learning curve, and is associated with less blood
loss, fewer complications, and an earlier return of bowel
function than is LRC [22]. Furthermore, 2 prospective,
controlled randomised trials, comparing RARC to open
RC, noted that RARC was associated with a significantly
decreased estimated blood loss, and a reduced transfusion
rate, operative time, and analgesic use. No significant dif-
ferences were observed regarding complications, length of
hospital stay, or pathological outcomes [23,24].
In our experience, pure LRC combined with orthotopic
neobladder creation in male patients with invasive bladder
carcinoma results is safe and feasible in terms of radical
tumour resection, and offers a minimally invasive proced-
ure with a quick recovery. With the improvement of lap-
aroscopic techniques and the development of innovative
equipment [5], the treatment of bladder cancer using pure
LRC and the creation of orthotopic neobladders is matur-
ing. Compared to the open procedure, this technique has
3 principal advantages. First, the technique offers a clearer
operative view, which facilitates meticulous dissection and
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the early postoperative recovery of continence. Second,
each dissection is performed with good hemostasis, and
the pneumo-peritoneal pressure can also decrease venous
haemorrhage. Third, the bowel is never exposed extracor-
poreally. We consider that the reduced invasiveness of the
bowel manipulation was associated, in our case series,
with quicker functional recovery of the intestinal tract and
decreased the incidence of related postoperative complica-
tions. This experience also addresses the concept that
LRC, with totally intracorporeal urinary diversion, is a
procedure for skilled surgeons and that significant laparo-
scopic experience is important to reduce the operative
time. Furthermore, the surgical strategy and the selection
of specific devices are crucial to simplify some of the crit-
ical steps of the procedure, such as ureteral stenting and
uretero-neobladder anastomosis. These aspects are essen-
tial to shortening the operation, which is mostly dedicated
to the reconstructive phase. Based on our experience, good
patient selection and a highly standardized procedure,
managed by a skilled surgical team, allows the achievement
of acceptable operative times and good oncologic and
functional outcomes. This experience may be reproduced
in many other institutions where expert surgeons have an
extensive laparoscopic background. Experienced surgeons,
assisted by expert teams, may reduce the operative time
for the configuration of the intracorporeal neobladder
to balance the time necessary to restore body integrity by
suturing the peritoneum, fascia, muscles, and skin during
an open procedure. These results should be supported
from experiences involving large cohorts of patients.
The main limitation of this study is the relatively small
sample size and the follow-up duration. However, the
primary aim of this study was to report our experience
with the technique, performed by one surgical team.
Nevertheless, a larger, multi-institutional analysis with a
longer follow-up period is needed to confirm that this
LRC approach, with open neobladder configuration,
achieves long-term oncologic and functional outcomes
superior to those achieved using open RC.
Conclusions
Pure LRC, with intracorporeal orthotopic ileal neobladder
reconstruction, may represent a viable alternative to open
radical cystectomy with a significant reduction in patient
morbidity. Future large, randomized controlled trials with
extensive follow-up are needed to confirm and update the
results of this study.
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